Literature DB >> 19732293

Signalling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases.

M Pertuit1, A Barlier, A Enjalbert, C Gérard.   

Abstract

Despite extensive research on sporadic pituitary adenomas, it is not yet possible to assign one protein alteration to one specific type of pituitary adenomas. Nevertheless, alterations of the cAMP pathway appear to be molecular hallmarks of most growth hormone (GH)-secreting adenomas. However, these alterations do not confer specific phenotypes to patients carrying these alterations. In this review, we summarise the literature regarding signalling alterations observed in GH-secreting adenomas. We focus on Gsalpha alterations and their possible cross-talk with the extracellular signal-related kinase (ERK)1/2 pathway. In the light of results obtained on human somatotroph adenoma cells in primary culture and on models of murine somatotroph cell lines, we postulate a crucial role for ERK1/2 in GH-secreting adenomas downstream of cAMP pathway alterations that might impact the tumoural phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732293     DOI: 10.1111/j.1365-2826.2009.01910.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  10 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities.

Authors:  Salahaldin A Tahir; Jianjun Gao; Yuji Miura; Jorge Blando; Rebecca S S Tidwell; Hao Zhao; Sumit K Subudhi; Hussein Tawbi; Emily Keung; Jennifer Wargo; James P Allison; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

3.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

4.  Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Pornsuk Cheunsuchon; Yunli Zhou; Xun Zhang; Hang Lee; Wendy Chen; Yuki Nakayama; Kimberley A Rice; E Tessa Hedley-Whyte; Brooke Swearingen; Anne Klibanski
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

5.  Genetic analysis of a patient with coexisting acromegaly, thyroid papillary carcinoma and subcutaneous fibroma.

Authors:  Jingfang Liu; Xulei Tang; Jianguo Cheng; Liting Wang; Xiaomei Yang; Yan Wang
Journal:  Oncol Lett       Date:  2014-12-23       Impact factor: 2.967

6.  DHA induces apoptosis of human malignant breast cancer tissues by the TLR-4/PPAR-α pathways.

Authors:  Lijing Geng; Wei Zhou; Bing Liu; Xinyun Wang; Bo Chen
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

7.  SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth via Targeting VEGFA.

Authors:  Xiaoyu Wang; Yuanjian Fang; Yunxiang Zhou; Xiaoming Guo; Ke Xu; Chenguang Li; Jianmin Zhang; Yuan Hong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-09       Impact factor: 5.555

Review 8.  cAMP Signalling Pathway in Biocontrol Fungi.

Authors:  Zhan-Bin Sun; Shu-Fan Yu; Chu-Lun Wang; Ling Wang
Journal:  Curr Issues Mol Biol       Date:  2022-06-04       Impact factor: 2.976

9.  The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.

Authors:  Alexandra M Fajardo; Gary A Piazza; Heather N Tinsley
Journal:  Cancers (Basel)       Date:  2014-02-26       Impact factor: 6.639

10.  Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors.

Authors:  Emilia Modolo Pinto; Fabio R Faucz; Luana Z Paza; Gang Wu; Elizabeth S Fernandes; Jerome Bertherat; Constantine A Stratakis; Enzo Lalli; Raul C Ribeiro; Carlos Rodriguez-Galindo; Bonald C Figueiredo; Gerard P Zambetti
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.